Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The company has a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases, as well as collaboration agreement with Johnson & Johnson to provide therapeutic solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.
तुलना करने के लिए मीट्रिक्स | RLYB | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधRLYBपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −4.9x | −2.7x | −0.5x | |
PEG अनुपात | −0.06 | 0.11 | 0.00 | |
क़ीमत/बुक | 0.8x | 2.7x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 51.0x | 29.6x | 3.2x | |
अपसाइड (विश्लेषक लक्ष्य) | −2.7% | 89.5% | 44.2% | |
उचित मूल्य अपसाइड | अनलॉक करें | 8.0% | 5.5% | अनलॉक करें |